Recall
FDAHealthJuly 6, 2026

Siemens Healthcare Diagnostics, Inc. — Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic

⚠️ Processing of urine albumin assay on the CI analyzers may lead to the following issues: Falsely depressed Atellica CH Urea Nitrogen (UN_c) results; Falsely depressed Atellica CH Enzymatic Hemoglobin A1c (A1c_E) results; Increased rate of reaction cuvette QC failures and Delayed results due to QC failures.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
July 6, 2026

Worldwide distribution - US Nationwide including Puerto Rico and the countries of Australia, Austria, Bahamas, Belgium, Brazil, Canada, Chile, Curacao, St. Eus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Israel,¿Italy,¿Latvia, Malaysia, Netherlands, New Zealand, Norway, Portugal, Republic of Korea, Romania, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United¿Kingdom.¿

What's affected?

Product
Atellica CH Urine Albumin REF: 11537225, in vitro diagnostic
Lot code
within

Additional details

All Lots within expiry/UDI: 00630414611099

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 7018 units.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.